Founded in 2015, Small Pharma was established to identify promising innovative treatment options for depression and other mental health conditions. Small Pharma trades on the TSX Venture Exchange under the ticker symbol “DMT”.
Small Pharma is developing enhanced DMT treatments to optimise therapies for mental health conditions. Small Pharma are developing N,N-dimethyltryptamine (DMT) and a pipeline of novel patent-protected deuterium-enriched tryptaminecompounds for psychedelic-assisted psychotherapy as a rapid onset, sustained treatment for mental health disorders. DMT benefits from being a safe & well tolerated drug with a short psychedelic experience.
With our first candidate, SPL026, Small Pharma has identified an expedited route to clinical proof-of-concept of DMT Therapy as a rapid-acting treatment for depression.